EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders

Yasuhito Suzuki, Junpei Saito, Masami Kikuchi, Suguru Sato, Atsuro Fukuhara, Mami Rikimaru, Hikaru Tomita, Kentaro Kazama, Koshi Saito, Rina Harigane, Riko Sato, Ryuki Yamada und 10 weitere

Allergology International · 2026-01 · 75 (1) · 52-61

DOI: 10.1016/j.alit.2025.05.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergology International, 2026-01. Verfasst von Yasuhito Suzuki und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan. Hauptthemen laut MEDLINE: Chitinase-3-Like Protein 1, Pulmonary Disease, Chronic Obstructive, Asthma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Corporation, JSPS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chitinase-3-like protein 1 (YKL-40) has been reported as a biomarker of neutrophilic airway inflammation in obstructive airway disorders. However, the pathophysiological features of YKL-40 remain unclear. The aim of the study is to evaluate the associations between YKL-40 and clinical features in patients with asthma, chronic obstructive pulmonary disease (COPD), or asthma-COPD overlap (ACO). METHODS: Serum and sputum YKL-40 levels were measured in 46 asthmatics, 35 COPD, and 32 ACO patients. RESULTS: Serum YKL-40 levels were elevated in the COPD and ACO patients, and sputum YKL-40 levels were higher in the COPD patients compared to the asthmatics. Both serum and sputum YKL-40 levels positively correlated with sputum neutrophils. Only serum YKL-40 levels negatively correlated with FEV1 (%predicted), FEV1/FVC, and annual decline in FEV1. In 15 patients whose paired serum samples were obtained within 6 months, changes in serum YKL-40 levels showed a significant positive correlation with those in FEV1. Furthermore, patients who had experienced exacerbations either in the past year or the following year showed significantly greater serum, but not sputum, YKL-40 levels. Sputum YKL-40 levels showed significant correlations with scores on the COPD assessment test and modified Medical Research Council dyspnea scale. CONCLUSIONS: Serum and sputum YKL-40 may reflect distinct clinical features in obstructive airway disorders. Serum YKL-40 may provide beneficial information on predicting obstructive neutrophilic inflammation and exacerbations, whilst sputum YKL-40 may offer valuable insights for evaluating ongoing symptoms. Concomitant measurement of YKL-40 in serum and sputum might be more useful than individual measurement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chitinase-3-Like Protein 1Pulmonary Disease, Chronic ObstructiveAsthmaHumansMaleFemaleMiddle AgedSputumBiomarkersAgedAdultNeutrophils

Stichwörter der Autor:innen

Airflow limitationBiomarkerExacerbationFEV(1)Neutrophilic inflammation

Substanzen

Chitinase-3-Like Protein 1BiomarkersCHI3L1 protein, human

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan. Electronic address: junpei@fmu.ac.jp.

Förderung

  • Novartis Pharmaceuticals Corporation
  • JSPS

Zitieren

APA

Suzuki, Y., Saito, J., Kikuchi, M., Sato, S., Fukuhara, A., Rikimaru, M., Tomita, H., Kazama, K., Saito, K., Harigane, R., Sato, R., Yamada, R., Watanabe, N., Umeda, T., Togawa, R., Sato, Y., Minemura, H., Nikaido, T., Kanazawa, K., …, & Shibata, Y. (2026). Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders. Allergology International, 75(1), 52-61. https://doi.org/10.1016/j.alit.2025.05.004

Vancouver

Suzuki Y, Saito J, Kikuchi M, Sato S, Fukuhara A, Rikimaru M, et al. Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders. Allergology International. 2026;75(1):52-61. doi:10.1016/j.alit.2025.05.004

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Yasuhito and Saito, Junpei and Kikuchi, Masami and Sato, Suguru and Fukuhara, Atsuro and Rikimaru, Mami and Tomita, Hikaru and Kazama, Kentaro and Saito, Koshi and Harigane, Rina and Sato, Riko and Yamada, Ryuki and Watanabe, Natsumi and Umeda, Takashi and Togawa, Ryuichi and Sato, Yuki and Minemura, Hiroyuki and Nikaido, Takefumi and Kanazawa, Kenya and Wang, Xintao and Tanino, Yoshinori and Shibata, Yoko},
  title = {Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders},
  journal = {Allergology International},
  year = {2026},
  volume = {75},
  number = {1},
  pages = {52--61},
  doi = {10.1016/j.alit.2025.05.004}
}
Kostenlos starten →